Daewoong Pharmaceutical "Autoimmune Treatment Candidate, COVID-19 Preclinical Government Support"
[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 22nd that its autoimmune therapeutic drug candidate 'DWP212525' has been selected for a government project on preclinical studies for COVID-19 treatment.
DWP212525 was selected for the "2020 Infectious Disease Prevention and Treatment Technology Development Project" supported by the Ministry of Health and Welfare, and will receive funding for preclinical research and development.
DWP212525 is a new drug candidate that selectively inhibits targets involved in immune cell activation. It has anti-inflammatory effects and protects tissues damaged by inflammation.
Daewoong Pharmaceutical aims to enter Phase 1 clinical trials for DWP212525 in the second half of next year.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
Seungho Jeon, CEO of Daewoong Pharmaceutical, said, "With the experience and know-how accumulated through clinical trials of COVID-19 treatments such as Hoistar tablets (Camostat) and DWRX2003 (Niclosamide), we will develop DWP212525 accurately and swiftly."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
